Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Privosegtor · BN-201, G-79

Small molecule · developed by Oculis

Phase 3 Most advanced trial
OCS Developer
1 Registered trials

What is Privosegtor?

Privosegtor is an investigational agent given intravenously at 3 mg/kg/day for 5 treatment days. It is studied in optic neuritis, a disease of the optic nerve.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BN-201, G-79
Drug type
Small molecule
Therapy area
Ophthalmology
Developer
Oculis (OCS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
KCN37L7EIH

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07623668 Phase 3 Optic Neuritis Recruiting OCS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Optic Neuritis

More from Oculis

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the OCS page.

Follow OCS, the company behind Privosegtor

See OCS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OCS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.